Skip to main content

Market Overview

Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings

  • Intra-Cellular Therapies Inc (NASDAQ: ITCIsubmits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults.
  • The application seeks approval for two indications of CAPLYTA; as monotherapy and as adjunctive therapy with lithium or valproate.
  • The Company anticipates an FDA target action date for the application in the second half of 2021.
  • CAPLYTA is indicated for the treatment of schizophrenia in adults.
  • Price Action: ITCI decreased 1.70% at $38.84 in market trading hours on the last check Monday.

Related Articles (ITCI)

View Comments and Join the Discussion!

Posted-In: bipolar disorderBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at